X

Trial Profile

A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IBC-Ab002 in Persons With Early Alzheimer's Disease (AD)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 11 Jun 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IBC Ab002 (Primary)
Indications Alzheimer's disease
Focus Adverse reactions; First in man
Sponsors ImmunoBrain Checkpoint

Most Recent Events

05 Jun 2024 Planned End Date changed from 1 Dec 2024 to 1 Nov 2025.
05 Jun 2024 Planned primary completion date changed from 1 Oct 2024 to 1 Nov 2025.
17 May 2023 According to an ImmunoBrain Checkpoint media release, the company has dosed the first two patients in this study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com